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Background: Nemaline myopathy (NM), the most common non-dystrophic congenital myopathy, is characterized
by generalized skeletal muscle weakness, often from birth. To date, no therapy exists that enhances the contractile
strength of muscles of NM patients. Mutations in NEB, encoding the giant protein nebulin, are the most common
cause of NM. The pathophysiology of muscle weakness in NM patients with NEB mutations (NEB-NM) includes a
lower calcium-sensitivity of force generation. We propose that the lower calcium-sensitivity of force generation in
NEB-NM offers a therapeutic target. Levosimendan is a calcium sensitizer that is approved for use in humans and
has been developed to target cardiac muscle fibers. It exerts its effect through binding to slow skeletal/cardiac
troponin C. As slow skeletal/cardiac troponin C is also the dominant troponin C isoform in slow-twitch skeletal
muscle fibers, we hypothesized that levosimendan improves slow-twitch muscle fiber strength at submaximal levels
of activation in patients with NEB-NM.
Methods: To test whether levosimendan affects force production, permeabilized slow-twitch muscle fibers isolated
from biopsies of NEB-NM patients and controls were exposed to levosimendan and the force response was measured.
Results: No effect of levosimendan on muscle fiber force in NEB-NM and control skeletal muscle fibers was
found, both at a submaximal calcium level using incremental levosimendan concentrations, and at incremental
calcium concentrations in the presence of levosimendan. In contrast, levosimendan did significantly increase the
calcium-sensitivity of force in human single cardiomyocytes. Protein analysis confirmed that the slow skeletal/
cardiac troponin C isoform was present in the skeletal muscle fibers tested.
Conclusions: These findings indicate that levosimendan does not improve the contractility in human skeletal
muscle fibers, and do not provide rationale for using levosimendan as a therapeutic to restore muscle weakness
in NEB-NM patients. We stress the importance of searching for compounds that improve the calcium-sensitivity
of force generation of slow-twitch muscle fibers. Such compounds provide an appealing approach to restore
muscle force in patients with NEB-NM, and also in patients with other neuromuscular disorders.
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Nemaline myopathy (NM) is the most common non-
dystrophic congenital myopathy (incidence approximately
1:50,000) [1]. Hallmark features of NM include muscle
weakness and the presence of nemaline bodies in muscle
fibers [2]. To date, ten genes have been implicated in NM.
Seven of these genes encode proteins of the skeletal
muscle thin filament (alpha-tropomyosin-3 and beta-
tropomyosin (TPM3 and TPM2), nebulin (NEB), actin
alpha 1 (ACTA1), troponin T type 1 (TNNT1), cofilin-2
(CFL2)), and leiomodin-3 (LMOD3) [3,4], and three genes
encode kelch domain proteins that are associated with
thin filament proteins and may be involved in regulating
thin filament protein stability or turnover (kelch repeat
and BTB (POZ) Domain Containing 13 (KBTBD13),
(kelch-like family member 40 (KLHL40) and kelch-like
family member 41 (KLHL41)) [5-11].
Mutations in NEB are the most common cause of
NM, accounting for more than 50% of NM cases [12,13].
Nebulin is a giant sarcomeric protein (approximately
800 kDa), and a single nebulin molecule spans nearly
the entire length of the thin filament. Previous studies of
a nebulin knockout mouse model showed that nebulin
stabilizes the thin filament and specifies its length
[14-18]. Evidence also suggests that nebulin modulates
both the kinetics of actomyosin cross-bridge formation
[19,20] and the calcium-sensitivity of thin filament acti-
vation [20,21]. Recent work revealed that skeletal muscle
fibers of NM patients with NEB mutations (NEB-NM)
develop muscle weakness due to loss of these functions
of nebulin; their myofibers contain thin filaments of
shorter length, they show altered actomyosin cross-
bridge kinetics [22-24], and they have a lower calcium-
sensitivity of force generation [23].
To date, no therapy exists that enhances force gener-
ation in NEB-NM. We propose that the lower calcium
sensitivity of force generation in NEB-NM offers a thera-
peutic target. Recent work from our group addressed the
ability of a fast skeletal muscle troponin activator to
enhance the calcium sensitivity of force generation in
skeletal muscle fibers from NEB-NM patients. These
troponin activators target fast-twitch muscle fibers [25],
and it was demonstrated that the compound increased
the calcium sensitivity of force generation in fast-twitch
fibers of NEB-NM patients [26]. As human skeletal mus-
cles consist of a mixture of fast- and slow-twitch muscle
fibers, it would be desirable to also target the calcium
sensitivity of slow-twitch muscle fibers in NM patients,
especially as these patients have been shown to have a
predominance of slow-twitch muscle fibers [2]. Levosi-
mendan is a calcium sensitizer that is approved for use
in humans and has been developed to target cardiac
muscle fibers. It exerts its effect through binding to slow
skeletal/cardiac troponin C and improves cardiaccontractility in vivo [27] and in vitro [28]. Slow skeletal/
cardiac troponin C is also the dominant troponin C
isoform in slow-twitch skeletal muscle fibers, and recent
work suggested that levosimendan improves submaximal
contractility of slow-twitch muscle fibers in the dia-
phragm of animal models and in humans [29-31].
Based on these findings, we hypothesized that levosi-
mendan improves slow-twitch muscle fiber strength at
submaximal levels of activation in patients with NEB-
NM. To test this hypothesis, we exposed muscle fibers
isolated from biopsies of NEB-NM patients to levosi-
mendan and measured the force response. Our findings
suggest that levosimendan does not improve the in vitro
contractility of slow-twitch muscle fibers at submaximal
activation levels in patients with NEB-NM.
Methods
Skeletal muscle biopsies of NEB-NM patients
Quadriceps muscle specimens, remaining from diagnostic
procedures or obtained during clinically indicated surgical
procedures, were collected from four NM patients with
confirmed NEB gene mutations and from three adult con-
trol subjects with no medical history. Ethical approval for
study of the NM biopsies was granted by the Institutional
Review Board of Boston Children’s Hospital, and these
biopsies were obtained from discarded clinical specimens
following informed consent under protocol 03-08-128R.
Details on the clinical and genetic data of the subjects
have been published previously (biopsy IDs T33, T1033,
T1069, and T887 [26]).
The three adult control muscle biopsies were obtained
under supervision of the HREC, Children’s Hospital at
Westmead (CHW/10/45). All biopsies were stored fro-
zen and unfixed at −80°C until use.
Skeletal muscle mechanics
Small strips dissected from the muscle biopsies were
permeabilized overnight as described previously [24].
This procedure renders the membranous structures in
the muscle fibers permeable, which enables activation of
the myofilaments with exogenous calcium. Preparations
were washed thoroughly with relaxing solution and
stored in 50% glycerol/relaxing solution at −20°C. Small
muscle bundles (cross-sectional area approximately 0.07
mm2, NEB-NM patients) and single muscle fibers (con-
trol subjects) were dissected from the permeabilized
strips and were mounted using aluminum T-clips be-
tween a length motor (ASI 403A, Aurora Scientific Inc.,
Ontario, Canada) and a force transducer element (ASI
315C-I, Aurora Scientific Inc., Ontario, Canada) in a
single fiber apparatus (ASI 802D, Aurora Scientific Inc.,
Ontario, Canada) that was mounted on the stage of an
inverted microscope (Zeiss Axio Observer A1, Zeiss,
Thornwood, NY, USA). Sarcomere length was set using
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(Aurora Scientific Inc., Ontario, Canada). Mechanical
experiments were performed at a sarcomere length of
2.1 μm, a length selected to minimize force differences
due to shorter thin filaments in fibers from NEB-NM
patients [24]. Fiber width and diameter were measured
at three points along the fiber, and the cross-sectional
area was determined assuming an elliptical cross sec-
tion. Three different types of bathing solutions were
used during the experimental protocols: a relaxing
solution (100 mM BES; 6.97 mM EGTA; 6.48 mM
MgCl2; 5.89 mM Na2-ATP; 40.76 mM K-propionate;
14.5 mM creatine phosphate), a pre-activating solution
with low EGTA concentration (100 mM BES; 0.1 mM
EGTA; 6.42 mM MgCl2; 5.87 mM Na2-ATP; 41.14 mM K-
propionate; 14.5 mM creatine phosphate; 6.9 mM HDTA),
and an activating solution (100 mM BES; 7.0 mM Ca-
EGTA; 6.28 mM MgCl2; 5.97 mM Na2-ATP; 40.64 mM
K-propionate; 14.5 mM creatine phosphate). The
temperature of the bathing solutions was kept constant
at 20°C using a TEC controller (ASI 825A, Aurora
Scientific Inc. Ontario, Canada).
Concentrated stock solutions of levosimendan (a kind
gift from Orion Pharma, Espoo, Finland) were prepared
in dimethyl sulfoxide (DMSO). Before use, levosimendan
stock solutions were diluted with experimental solutions.
The final concentration of DMSO did not exceed 0.03%.
Control experimental solutions contained 0.03% DMSO
(vehicle). To determine a dose-response curve for levosi-
mendan in muscle fibers from controls (CTRL) and
from NEB-NM patients, tissue was exposed to an acti-
vating solution with a pCa of 5.8 (CTRL) or pCa 5.6
(NEB-NM) - these pCas yielded approximately 40% of
maximal active tension - with vehicle (to establish the sub-
maximal force generation at that calcium concentration).
Subsequently, tissue was exposed to a similar activating
solution, but which contained increasing concentrations
of levosimendan (0.1, 1, 10, 25, and 100 μM). After expos-
ure to the final levosimendan concentration, the fibers
were once more activated in vehicle to rule out rundown
of force. Note that 0.03% DMSO did not affect muscle
fiber contractility (data not shown).
Finally, to determine the effect of levosimendan (100
μM) on the force-pCa relation, permeabilized muscle fiber
bundles or single fibers were sequentially bathed in a
relaxing solution, a pre-activation solution, and solutions
with pCa values ranging from 9.0 to 4.5 - all containing
100 μM levosimendan - and the steady-state force was
measured. Measured force values were normalized to the
maximal force obtained at pCa 4.5. The obtained force-
pCa data were fit to the Hill equation (Y = 1/(1 +
10nH(pCa − pCa50))) where the pCa50 corresponds to the
calcium concentration that yields half-maximal force and
the Hill coefficient, nH, to myofilament cooperativity [32].Myocardial human biopsies
Human left ventricular tissue was obtained from three
non-failing donors of whom the myocardium was not
required for transplantation. Donors had no history of
cardiac abnormalities, normal ECG, and normal ven-
tricular function on echocardiography within 24 h of
heart transplantation. Tissue was collected in cardio-
plegic solution and immediately frozen and stored in
liquid nitrogen. Samples were obtained after written
informed consent and with approval of the local Hu-
man Research Ethics Committee of the University of
Sydney (#7326). The investigation conforms with the
principles outlined in the Declaration of Helsinki
(1997).Cardiomyocyte mechanics
Cardiac tissue samples were thawed in relaxing solution
(5.95 mM Na2-ATP, 6.04 mM MgCl2, 2 mM EGTA,
139.6 mM KCl, 10 mM Imidazole, pH 7.0), and cardio-
myocytes were mechanically isolated by tissue disruption.
Thereafter, cardiomyocytes were chemically permeabilized
by incubation for 5 min in relaxing solution containing
0.5% (v/v) Triton-X100 and glued between a force trans-
ducer and a piezoelectric motor as described previously
[33]. Isometric force measurements were performed at a
submaximal calcium concentration (pCa 5.6), which gen-
erates 44% ± 5% of maximal force at saturating calcium
levels (pCa 4.5). Sarcomere length was adjusted to 1.8 μm
and determined by means of a spatial Fourier transform-
ation as described previously [33].
Levosimendan was dissolved in DMSO and diluted in
pCa 5.6 calcium batches to a final concentration ran-
ging from 0.1 to 100 μM. The final DMSO concentra-
tion did not exceed 0.03%. To control for artificial side
effects resulting from DMSO, the latter was diluted in
pCa 5.6 (DMSO final concentration <0.03%) and served
as control, herein termed as vehicle. No difference in
developed force was found between pCa 5.6 compared
with vehicle up to the maximum concentration levosi-
mendan used.Myosin heavy chain composition
A specialized sodium dodecyl sulfate polyacrylamide
gel electrophoresis (SDS-PAGE) was used to determine
the myosin heavy chain isoform composition of the
muscle fiber preparations that we used in our contract-
ility experiments [24]. In brief, muscles fibers were de-
natured by boiling for 2 min in SDS sample buffer. The
stacking gel contained a 4% acrylamide concentration
(pH 6.7), and the separating gel contained 7% acryl-
amide (pH 8.7) with 30% glycerol (v/v). The gels were
run for 24 h at 15°C and a constant voltage of 275 V.
Finally, the gels were silver-stained, scanned, and
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MD, USA) software.Troponin C Western blotting
Muscle samples were solubilized as described previ-
ously [34]. In brief, frozen muscle samples were ho-
mogenized in a liquid nitrogen cooled mortar and
re-suspended in 1 ml cold 10% trichloracetic acid
(TCA) solution dissolved in acetone containing dithio-
threitol (DTT) (0.2% w/v) and stored at −80°C for 60
min. Subsequently, homogenates were brought to room
temperature stepwise: 20 min at −20°C, 20 min at 4°C,
and 20 min at room temperature (while being mixed on
a vortex in between all steps). Then, muscle homoge-
nates were centrifuged at 12,000g for 15 min followed
by washing the tissue pellets with 1 ml of 0.2% w/v
DTT-acetone solution and shaking them for 5 min at
room temperature. This cycle of centrifugation, wash-
ing, and shaking was repeated five times. Tissue pellets
were freeze-dried overnight and homogenized in sam-
ple buffer containing 15% glycerol, 62.5 mM Tris (pH
6.8), 1% w/v SDS, and 2% w/v DTT (final concentration
5 μg dry weight/μl).
To discriminate between both slow skeletal/cardiac
troponin C and fast skeletal troponin C isoforms, 4 μl of
muscle homogenates in 1-D sample buffer (20 μg of dry
weight tissue) were loaded on a 15% acrylamide SDS-
PAGE gel. Subsequently, the gel ran first for 20 min at 200
V and thereafter 160 min at 400 V at 15°C. After comple-
tion of the run, the gel was blotted for 90 min at constant
amperage of 320 mA using a semidry blotting system
(Trans-Blot SD Cell, Bio-Rad, Hercules, CA, USA). After
staying overnight in blocking solution (5% milk in TBS-T),
the blot was incubated at room temperature for 90 min in
a pan-specific antibody directed against troponin C
(#4002, Cell Signaling, Boston, MA, USA) (1:500 in block-
ing solution), washed for 30 min and put in secondary
antibody goat anti-rabbit HRP (Dako, Glostrup, Denmark)
(1:2,500 in blocking solution) for 60 min at room
temperature. Thereafter, the blot was washed with TBS-T
for 30 min and treated with ECL prima reagents (GE
Healthcare, Buckinghamshire, UK) for 5 min. The blot
was scanned using a LAS 3000 (Fujifilm Medical Systems,
Stamford, CT, USA).Statistical analyses
Data are presented as mean ± SEM. For statistical ana-
lyses, t test, one-way ANOVA, and two-way ANOVA
were used. For dose-response tests, one-way repeated
measures ANOVA was used, with Dunnett’s Multiple
Comparison Test as post hoc test. P < 0.05 was consid-
ered to be statistically significant.Results
The contractile performance of permeabilized muscle
fibers from nemaline myopathy patients with nebulin
mutations
Muscle contractility experiments
The force-generating capacity of permeabilized muscle
fiber bundles isolated from nemaline myopathy biopsies
with mutations in the nebulin gene (NEB-NM) was
lower compared to muscle fibers from healthy controls
at both maximal and submaximal calcium levels (for
typical force traces see Figure 1A). At pCa 4.5 - corre-
sponding to a calcium concentration that yielded max-
imal force generation - NEB-NM muscle fiber bundles
revealed a significant lower force-generating capacity
(19 ± 3 mN/mm2) compared to slow-twitch single fibers
from control biopsies (CTRLslow) (133 ± 11 mN/mm
2)
and fast-twitch single fibers from control biopsies
(CTRLfast) (172 ± 8 mN/mm
2) (Figure 1B). In addition,
at submaximal calcium levels (pCa 5.8), NEB-NM
muscle fibers (7 ± 2 mN/mm2) were significantly weaker
than CTRLslow (58 ± 6 mN/mm
2) and CTRLfast fibers
(49 ± 4 mN/mm2) (Figure 1C).
Interestingly, when expressing the force generating
capacity of the muscle fibers at a submaximal calcium
concentration (pCa 5.8) as a percentage of the maximal
force-generating capacity (pCa 4.5, Fmax), NEB-NM
muscle fibers reveal a significant lower relative con-
tractile performance at submaximal calcium levels
(24%Fmax ± 2%Fmax) compared to CTRLslow (43%Fmax ±
2%Fmax) and CTRLfast fibers (37%Fmax ± 3%Fmax)
(Figure 1D). This observation indicates that NEB-NM
muscle fibers have a lower calcium sensitivity of force
than fibers from controls.
Myosin heavy chain composition
As the force-generating capacity of muscle fibers de-
pends on the myosin heavy chain isoform composition,
we determined the relative abundance of slow myosin
isoforms (MHCslow) and fast myosin isoforms MHC 2A
and 2× (MHCfast) in the single fibers of control subjects
and the muscle fiber bundles of NEB-NM patients that
were used for the contractility experiments. Our analyses
showed that NEB-NM muscle bundles were composed
of 75% ± 6%MHCslow and of 25% ± 6%MHCfast (Figure 1E).
Thus, the biopsies of the NEB-NM patients contained pre-
dominantly slow-twitch muscle fibers.
The effect of levosimendan on force in permeabilized
skeletal muscle fibers
Dose-response relation
We tested levosimendan at a range of concentrations
and at a pCa that yielded approximately 40% of maximal
force in both NEB-NM fibers and CTRL fibers. In both
NEB-NM muscle bundles that expressed solely MHCslow
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Figure 1 Typical force traces, maximal tension, submaximal tension, relative submaximal tension, and specialized SDS-PAGE gel example. (A) Typical
force trace of a slow-twitch single muscle fiber of a control subject and of a muscle fiber bundle of a NEB-NM patient (biopsy ID T33 is shown) during
exposure to an experimental solution with pCa 4.5. Note the severely reduced maximal tension of the muscle fibers of the NEB-NM patient.
(B) Maximal tension (pCa 4.5) of muscle fibers of healthy controls and NEB-NM patients. (C) Submaximal tension (pCa 5.8) of muscle fibers of
healthy controls and NEB-NM patients. (D) Relative submaximal tension (pCa 5.8/4.5). Note that the relative submaximal tension of muscle fibers of
NEB-NM patients is reduced, indicating a reduced calcium sensitivity of force. (E) Example of a specialized SDS-PAGE gel that was used to determine
the myosin heavy chain isoform composition of the muscle fiber preparations that we used in our contractility experiments. Here, the bundle from
NEB-NM T33 is composed of type 1 myosin heavy chain isoforms (MHC 1), the bundle from NEB-NM T887 contains both MHC 1 and type 2A myosin
heavy chain isoforms (MHC 2A), and the marker exhibits both MHC 1 and MHC 2A as myosin 2X isoforms (MHC 2X). NEB-NM, nemaline myopathy
patients with mutations in the nebulin gene; NS, not significant. *P < 0.05.
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MHCslow and MHCfast, no effect of levosimendan on
force was observed at any of the concentrations tested
(Figure 2A,B). Muscle of these NEB-NM patients is
nebulin-deficient (as reported previously [26]). To verify
whether an effect of levosimendan on force was blunted
by nebulin deficiency of NEB-NM muscle fibers, we also
performed dose-response experiments on CTRLslow and
CTRLfast muscle fibers at approximately 40%Fmax.
Again, it was observed that none of the concentrations
tested an effect of levosimendan on muscle fiber force
(Figure 2C,D).Force-pCa curve
The dose-response experiments were performed at a
single pCa, and therefore we also studied the effect of
levosimendan on fiber force at a range of calcium
concentrations. In NEB-NM muscle fibers, no shift of
the force-pCa curve was observed upon exposure to
100 μM levosimendan (Figure 3A,B), as reflected by no
change in the pCa50 value (5.52 ± 0.01 vs. 5.53 ± 0.02,
levosimendan in vehicle vs. vehicle alone, respectively)
and no change in nH, a measure of cooperativity of
activation (2.06 ± 0.16 vs. 2.07 ± 0.12, levosimendan in
vehicle vs. vehicle alone, respectively).
CTRL (type slow, n = 12)
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Figure 2 The effect of incremental concentrations of levosimendan on submaximal force (approximately 40% of maximal force) of NEB-NM
slow-twitch (A) and mixed (B) muscle fibers. Prior to and directly after exposure to the levosimendan concentrations, fibers were exposed to
vehicle to rule out confounding effects of force rundown during the protocol. Note that levosimendan did not increase force compared to vehicle.
Similar results were observed in slow-twitch (C) and fast-twitch (D) muscle fibers of control subjects. NEB-NM, nemaline myopathy patients with
mutations in the nebulin gene; CTRL, control.
de Winter et al. Skeletal Muscle  (2015) 5:12 Page 6 of 10Thus, we observed no effect of levosimendan on muscle
fiber force in NEB-NM and CTRL skeletal muscle fibers,
neither at a submaximal calcium level using incremental
levosimendan concentrations nor at incremental calcium














Figure 3 No shift of the force-pCa curve was observed upon exposure to
force-pCa relation of muscle fibers of NEB-NM patients, as reflected by the
nemaline myopathy patients with mutations in the nebulin gene; NS, not sThe effect of levosimendan on force in human
cardiomyocytes
As previous work showed that levosimendan augments
submaximal force in cardiomyocytes [28], we next


































100 μM levosimendan. (A) Levosimendan (100 μM) did not affect the
unaltered pCa50 (B, left panel) and nHill (B, right panel). NEB-NM,
ignificant.
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typical force traces). These experiments revealed a sig-
nificant dose-dependent increase of submaximal force
in human cardiomyocytes at levosimendan concentra-
tions of 1 μM (115% ± 2% of vehicle), 25 μM (125% ±
4% of vehicle), and 100 μM (131% ± 8% of vehicle)
(Figure 4B). Thus, we confirmed the efficacy of levosi-
mendan in human cardiomyocytes.
Slow skeletal/cardiac troponin C levels in skeletal muscle
fibers of NEB-NM patients
Levosimendan exerts its calcium-sensitizing effect by
binding to slow skeletal/cardiac troponin C. As we ob-
served no effect of levosimendan in slow-twitch skeletal
muscle fibers, we tested whether these fibers indeed
expressed slow skeletal/cardiac troponin C isoforms.
Figure 5 shows that NEB-NMslow muscle fibers, NEB-
NMmixed muscle fibers, and CTRLslow muscle fibers ex-
press the slow skeletal/cardiac troponin C isoform. Thus,
slow skeletal/cardiac troponin C, the isoform through
which levosimendan exerts its effect, was abundantly
expressed in NEB-NM and CTRLslow muscle samples.
Discussion
A reduced calcium sensitivity of force generation con-
tributes to muscle weakness in NEB-NM muscle. There-
fore, in the present study, we aimed to test the ability of
levosimendan, the only calcium sensitizer approved for
use in humans, to improve the calcium sensitivity of
force generation in slow-twitch muscle fibers of NEB-NM
patients. Our findings indicate that levosimendan does














Figure 4 Typical force trace and the effect of incremental concentrations of
cardiomyocyte. Force increases while exposing the cardiomyocyte to an expe
Relaxation is induced by exposing the cardiomyocyte to an experimental solu
incremental concentrations of levosimendan on submaximal force (approxima
after exposure to the levosimendan concentrations, cardiomyocytes were expo
the protocol. Note that at various concentrations (1, 25, and 100 μM) levosimenslow-twitch muscle fibers isolated from biopsies of NEB-
NM patients.Submaximal force generation is lower in muscle fibers
from NEB-NM patients compared to that in muscle fibers
from controls
The severe reductions in force levels generated by fibers
of NEB-NM patients are caused by contractile deficits due
to defects in sarcomeric proteins [35], rather than lower
neural activation, ineffective excitation-contraction coup-
ling, or other non-contractile defects. Mechanisms that
contribute to weakness of muscle fibers in NEB-NM
include myofibrillar disarray [3,22], shorter thin filaments
[24], altered cross-bridge cycling kinetics [19,20], and a
reduced calcium sensitivity of force generation [20,21].
The NEB-NM samples studied here were from the same
cohort as studied recently by de Winter and coworkers
[26]. In that study, it was shown that muscle fibers of
NEB-NM patients have a lower calcium sensitivity of force
generation compared to fibers from control subjects [26].
Here, we confirmed these findings on freshly isolated
fibers from biopsies of these patients. Figure 1 illustrates
that at pCa 5.8 - a pCa that yields submaximal force - the
force generated, relative to maximal force, is lower in
NEB-NM fiber bundles when compared to fibers from
control subjects. As discussed previously, the lower cal-
cium sensitivity of force in NEB-NM fibers is likely to be
caused, at least in part, by nebulin deficiency [20,21]. Note
that previous work indicated that muscle fibers in the
biopsies of these patients contained approximately 25% of
normal nebulin levels [26].Cardiomyocytes (n = 13)





levosimendan on submaximal force. (A) Typical force trace of a human
rimental solution with submaximal exogenous calcium levels (pCa 6.5).
tion with a very low calcium concentration (pCa 9.0). (B) The effect of
tely 40% of maximal force) of human cardiomyocytes. Prior to and directly
sed to vehicle to rule out confounding effects of force rundown during
dan significantly increased submaximal force. *P< 0.05.
Troponin C isoform expression










Fast skeletal troponin C
Slow skeletal/cardiac troponin C
Figure 5 Western blot example, with anti-TnC antibody, including muscle homogenates of human diaphragm muscle (which is known to contain
both slow skeletal/cardiac troponin C and fast skeletal troponin C), human left ventricle (which also contains slow skeletal/cardiac troponin C), and
quadriceps muscle of NEB-NM patients (biopsy IDs T33 and T1069 are shown) and healthy controls. Note that slow skeletal/cardiac troponin C is
abundant in NEB-NM muscle. NEB-NM, nemaline myopathy patients with mutations in the nebulin gene; CTRL, control; MHC, myosin heavy chain.
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NEB-NM muscle fibers
Targeting the reduced calcium sensitivity of force is an
appealing approach to combat muscle weakness in NEB-
NM patients. Recently, we tested the ability of a fast
skeletal troponin activator to restore force of fast-twitch
muscle fibers of NM patients [26] and of a mouse model
for NEB-NM [21]. Fast skeletal troponin activators
selectively sensitize the sarcomeres of fast-twitch skeletal
muscle fibers to calcium ions by increasing the affinity
of fast skeletal troponin C to calcium [25]. As neuro-
muscular input results in calcium release in the muscle,
the increased calcium sensitivity will enhance submaxi-
mal muscle strength. We have shown that fast skeletal
troponin activators augment the in vitro contractile
strength of muscle fibers of NEB-NM patients and NEB-
NM mice; the calcium sensitivity of force generation
even increased to levels higher than that observed in
healthy, untreated, control muscle [21,26].
Skeletal muscles are, however, composed of a mixture
of fast- and slow-twitch fibers, and their proportion
varies between muscles. For instance, in healthy humans,
the quadriceps muscle contains approximately 50%
slow-twitch fibers, while in the soleus muscle more than
80% of fibers are of the slow-twitch type. During activa-
tion of an individual muscle, first the motor units that
comprise of slow-twitch muscle fibers are the first ones
recruited. Subsequently, and only if required, the larger
motor units that consist of fast-twitch fibers are re-
cruited. In addition, NM patients typically exhibit a shift
towards a larger proportion of slow-twitch fibers [2].
These factors highlight the therapeutic opportunity of
improving the calcium sensitivity of force of slow-twitch
muscle fibers in NEB-NM patients.
Levosimendan was developed to increase the calcium
sensitivity of cardiac muscle to enhance contractility in
the failing heart [28,36]. It binds to slow skeletal/cardiac
troponin C, encoded by the TNNC1 gene, and stabilizes
the conformation of the troponin complex [36]. Slow
skeletal/cardiac troponin is also the dominant troponin
C isoform in slow-twitch skeletal muscle fibers, suggest-
ing that levosimendan could also improve the calciumsensitivity of slow-twitch muscle fibers. Indeed, recent
work showed that slow-twitch diaphragm muscle fibers
of patients with chronic obstructive pulmonary disease
had an increased submaximal force after exposure to
levosimendan [31]. Furthermore, in vivo administration
of levosimendan improved diaphragm contractility in
healthy subjects [29]. More specifically, the latter study
showed that levosimendan improved the neuromechani-
cal efficiency and reduced the development of fatigue of
the human diaphragm during loading tasks in vivo [29].
These findings highlight that the potential benefit of cal-
cium sensitizers includes not only increased force devel-
opment but also increased efficiency by reducing the
amount of cytosolic calcium that is required to generate
a given level of force. The energy utilization of SERCA
accounts for 30% to 40% of total ATP consumption
during muscle contraction [37,38]. Therefore, the use
of a calcium sensitizer has the potential to reduce the
amount of calcium that cycles each contraction and
thereby reduce muscle fatigue. This might be especially
beneficial for the respiratory muscles in patients with
NM, considering that respiratory failure due to dia-
phragm weakness is the main cause of death in neo-
nates with NM [2].
These previous findings with levosimendan provided an
impetus to study its effect on slow-twitch muscle fibers of
NEB-NM fibers. However, to our surprise, we observed no
effect of levosimendan on submaximal force of slow-
twitch muscle fibers of NEB-NM patients (Figures 2 and
3). Similarly, slow-twitch fibers of control subjects showed
no response to levosimendan. Note that we also tested
levosimendan in slow-twitch human diaphragm muscle
fibers - the muscle type that revealed positive results in
previous studies [30,31] - but we observed no effect on
the calcium sensitivity of force generation (see Additional
file 1: Figure S1). It should be noted that the lack of a
response to levosimendan was not caused by ‘defective’
levosimendan. We ruled out this possibility by testing the
effect of levosimendan on human cardiomyocytes, and in
line with extensive previous work (for instance [28,39,40]),
we observed a significant increase in the calcium sensitiv-
ity of force after exposure to levosimendan (Figure 4).
de Winter et al. Skeletal Muscle  (2015) 5:12 Page 9 of 10Furthermore, we evaluated whether slow-twitch muscle
fibers of control and NEB-NM biopsies contained slow
skeletal/cardiac troponin C isoforms. As shown in Figure 5,
these fibers did indeed contain slow skeletal/cardiac
troponin C. Thus, the absence of a response to levosimen-
dan in slow-twitch muscle fibers was not caused by defi-
ciency of slow skeletal/cardiac troponin C. Unfortunately,
we cannot provide a plausible explanation for the discrep-
ancy between our findings and those from previous stud-
ies that did show a response of slow-twitch fibers to
levosimendan [30,31].
Conclusions
In conclusion, the ex vivo findings with isolated muscle fi-
bers do not provide rationale for levosimendan as a thera-
peutic to restore muscle weakness in NEB-NM patients.
Future studies, to be performed by independent laborator-
ies, should confirm these findings. We stress the import-
ance of searching for compounds that improve the
calcium sensitivity of force of slow-twitch muscle fibers.
For instance, future research could test the efficacy of, not
yet registered, compounds such as EMD57033 and pimo-
bendan [41]. These compounds may be able to restore
muscle force not only in patients with NEB-NM but also
in patients with other neuromuscular disorders.
Additional file
Additional file 1: Figure S1. Levosimendan in human diaphragm
muscle fibers. The effect of incremental concentrations of levosimendan
on submaximal force (pCa 5.8, which yielded approximately 40% of
maximal force) of individual slow-twitch fibers from human diaphragm
(n = 7). Dose-force response experiments were performed according to
the protocol reported in the ‘Methods’ section. Single muscle fibers were
isolated from a diaphragm muscle biopsy that was obtained from a patient
that underwent resection of an early lung malignancy (male, age 64). The
biopsy protocol was approved by the institutional review board at VU
University Medical Center Amsterdam (#2010/69). Written informed
consent was obtained from the patient.
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